Erlotinib improves progression-free survival as first-line therapy in advanced lung cancer, study finds
Sunday, October 17, 2010 - 21:41
in Health & Medicine
For patients with advanced lung cancer whose tumors carry EGFR activating mutations, first-line treatment with erlotinib nearly tripled progression-free survival compared to a standard chemotherapy combination, show results from the first prospective Phase III study to report findings in this setting.